George Yancopoulos (courtesy Regeneron)
Looking past COPD, Regeneron CSO George Yancopoulos says Dupixent's 'next big thing' is reversing allergies
SAN FRANCISCO — While Dupixent could add a major new indication in COPD this year, Regeneron’s longtime top scientist is already excited by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
